109 related articles for article (PubMed ID: 20812278)
1. Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells.
Freudlsperger C; Dahl A; Hoffmann J; Reinert S; Schumacher U
Phytother Res; 2010 Sep; 24(9):1354-8. PubMed ID: 20812278
[TBL] [Abstract][Full Text] [Related]
2. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
Freudlsperger C; Thies A; Pfüller U; Schumacher U
Anticancer Res; 2007; 27(1A):207-13. PubMed ID: 17352234
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells.
Felenda JE; Turek C; Stintzing FC
J Ethnopharmacol; 2019 May; 236():100-107. PubMed ID: 30840914
[TBL] [Abstract][Full Text] [Related]
4. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
5. Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro.
Thies A; Nugel D; Pfüller U; Moll I; Schumacher U
Toxicology; 2005 Feb; 207(1):105-16. PubMed ID: 15590126
[TBL] [Abstract][Full Text] [Related]
6. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
9. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs.
Weber K; Mengs U; Schwarz T; Hajto T; Hostanska K; Allen TR; Weyhenmeyer R; Lentzen H
Arzneimittelforschung; 1998 May; 48(5):497-502. PubMed ID: 9638318
[TBL] [Abstract][Full Text] [Related]
10. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
Smith AG; Beaumont KA; Smit DJ; Thurber AE; Cook AL; Boyle GM; Parsons PG; Sturm RA; Muscat GE
Int J Biochem Cell Biol; 2009 Apr; 41(4):844-52. PubMed ID: 18822385
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
[TBL] [Abstract][Full Text] [Related]
12. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.
Yee LD; Williams N; Wen P; Young DC; Lester J; Johnson MV; Farrar WB; Walker MJ; Povoski SP; Suster S; Eng C
Clin Cancer Res; 2007 Jan; 13(1):246-52. PubMed ID: 17200362
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
[TBL] [Abstract][Full Text] [Related]
15. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro.
Valentiner U; Carlsson M; Erttmann R; Hildebrandt H; Schumacher U
Toxicology; 2005 Sep; 213(1-2):157-68. PubMed ID: 16009482
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
17. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro.
Freudlsperger C; Moll I; Schumacher U; Thies A
Anticancer Drugs; 2006 Mar; 17(3):325-32. PubMed ID: 16520661
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines.
Urech K; Buessing A; Thalmann G; Schaefermeyer H; Heusser P
Anticancer Res; 2006; 26(4B):3049-55. PubMed ID: 16886633
[TBL] [Abstract][Full Text] [Related]
19. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
Emery MN; Leontiou C; Bonner SE; Merulli C; Nanzer AM; Musat M; Galloway M; Powell M; Nikookam K; Korbonits M; Grossman AB
Clin Endocrinol (Oxf); 2006 Sep; 65(3):389-95. PubMed ID: 16918962
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
